Daniel O’Day: Gilead Sciences announces third quarter financial results
Daniel O’Day, Chairman and Chief Executive Officer of
“Today, we announced our third quarter earnings. Many thanks to the entire Gilead Sciences team who contributed to our success. This was the strongest quarter of the year, with a +7% year-over-year increase across our therapies for HIV, Oncology, and Liver Disease.
Our PURPOSE 2 study demonstrated remarkable efficacy in preventing HIV infection with our innovative, investigational twice-yearly dose—another signal that we’re on the precipice of helping to end the global fight to end the HIV/AIDS epidemic. We’re on track to submit for FDA approval by the end of the year, with a commercial launch planned for 2025. Another highlight for the third quarter was our launch of a new treatment for primary biliary cholangitis, providing a much-needed option for patients living with PBC.
These results reflect what makes us who we are—a company that prioritizes innovation and takes bold steps to increase our impact on patients and community. We feel confident in the future and are in a strong position to make strategic decisions and investments to catalyze future growth.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023